Adrafinil: A novel vigilance promoting agent

CNS Drug Reviews

Volumn 5, Issue 3, 1999, Pages 193-212

  Milgram, Norton W ^a   Callahan, Heather ^a   Siwak, Christina ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adrafinil; Age associated memory disorder; Eugregorics; GABA; Glutamate; Modafinil; Norepinephrine; Vigilance disorders

Indexed keywords

ADRAFINIL; MODAFINIL;

ALERTNESS; ALZHEIMER DISEASE; COGNITIVE DEFECT; DEMENTIA; DRUG ACTIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; HUMAN; MOTOR DYSFUNCTION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; REVIEW;

EID: 0032733740     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1999.tb00100.x     Document Type: Review

References (61)

1. Akaoka H, Roussel B, Lin J-S, Chouvet G, Jouvet M. Effect of modafinil and amphetamine on the rat catecholaminergic neuron activity. Neurosci Lett 1991;123:20-22.
2. Bastuji H, Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiatry 1988;12:695-700.
3. 1 noradrenergic control on the cortical release of acetylcholine and γ-aminobutyric acid in morphine tolerant guinea-pig. J Pharmacol Exp Ther 1988;247:294-301.
4. Besset A, Tafti M, Villemin E, Billiard M. Effet du modafinil (300 mg) sur le sommeil, la somnolence et la vigilance du narcoleptique. Neurophysiol Clin 1993;23:47-60.
5. Billiard M, Disdsoubray C, Lubin S, Cadilhad J. Short and long-term effects of modafinil in narcoleptic and in ideopathic hypersomniac patients. In: Home J, ed. Sleep 88. Proceedings of the 9th European Congress on Sleep Research: Jerusalem, Israel; 1988. Stuttgart: Gustav Fisher Verlag 1989;301-303.
6. Boivin DB, Montplaisir J, Petit D, Lambert C, Lubin S. Effects of modafinil on symptomatology of human narcolepsy. Clin Neuropharamacol 1993;16(1):46-53.
7. Boyer P. Age et performance cognitives, plaintes mnesiques et attentionnelles au quotidien. Synapse spécial "Vers une medecine des comportements," 1994:1-4.
8. Boyer P, Weil JS, Lubin S, Von Frenckell R. Inhibition de l'action et handicap idéomoteur. Résultats d'une étude controlée adrafinil (Olmifon®) versus placebo. Synapse 1991:81.
9. Broughton RJ, Fleming JAE, George CFP, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997;49:444-451.
10. Burnat P, Robles F, Do B. High-performance liquid chromatographic determination of modafinil and its two metabolites in human plasma using solid-phase extraction. J Chromatogr 1998;706:295-304.
11. Callahan H, Condron B, Milgram NW, MacKay WA. Neurophysiological modulation of cortical function by adrafinil, a novel psychomotor stimulant. (In preparation).
12. Chariot J, Appia F, Vaille C, Rozé C. Effect of modafinil on pancreatic exocrine secretion in rats. A comparison with adrafinil and related drugs. Fundam Clin Pharmacol 1987;1:243-252.
13. Chennat R, Doaré L, Lachapelle F, Simon P. Effects of drugs affecting the noradrenergic system on convulsions in the quaking mouse. Naunyn Schiedeberg's Arch Pharmacol 1981;318:94-99.
14. Crook TH III. Assessment of drug efficacy in age-associated memory impairment. In: Wurtman RJ et al., eds. Advances in Neurology, 51. Alzheimer's Disease. New York: Raven Press, 1990.
15. Crook R, Bartus RT, Ferris SH, et al. Age-associated memory impairment: Proposed diagnostic criteria and measures of clinical change-report of a National Institute of Mental health work group. Dev Neuropsychol 1986;24:261-276.
16. Defrance D, Raharison S, Hervé MA, Fondaraï J Bétrancourt JC, Lubin S. Malade âgés institutionnalisés et Olmifon® (adrafinil): détermination d'un profil de "répondeurs" à l'occasion d'un "effect centre" lors d'un essai contrôlé versus placebo. Actual Med Int Psychiatr 1991;8:1815-1823.
17. Delini-Stula A, Hunn C. Effects of single and repeated treatment with antidepressants on the apomorphine-induced yawning in the rat: The implication of α-1 adrenergic mechanisms in the D-2 receptor function. Psychopharmacology 1990;101:62-66.
18. Dewailly P, Durocher AM, Durot A, et al. Adrafinil et ralentissement du sujet âgé institutionnalisé: De la significativité statistique à la pertinence clinique (résultat d'une étude multicentrique en double aveugle versus placebo). Actual Med Int Psychiatr 1989;6:1-8.
19. Doaré L, Lachapelle F, Puech AJ, Chermat R, Simon P. Convulsive seizures in quaking mice: A model for studying a central noradrenergic system? Proceedings of the 12th Congress of CINP; Göteberg, Sweden; 1980. Abstract 171.
20. Doty BA, Doty LA. Facilitative effects of amphetamine on avoidance conditioning in relation to age and problem difficulty. Psychopharmacology (Berl) 1966;9:234-241.
21. Duteil J, Rambert FA, Pessonnier J, Gombert R, Assous E. A possible alpha-adrenergic mechanism of drug (CRL 40028)-induced hyperactivity. Eur J Pharmacol 1979;59:121-123.
22. Edgar DM, Seidel WF. Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat. J Pharmacol Exp Ther 1997;283:757-769.
23. Engber TM, Koury EJ, Dennis SA, Miller MS, Contreras PC, Bhat RV. Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil. Neurosci Lett 1998;241:95-98.
24. Ferner U, Matejcek M, Neff G. Confirmatory and exploratory analysis applied to pharmaco-EEG and related study data: Contradiction or useful enrichment? Neuropsychobiology 1983;9:182-192.
25. 3 receptor. Neurosci Lett 1996;220:5-8.
26. Ferraro L, Tanganelli S, O'Connor WT, Antonelli T, Rambert F, Fuxe E. The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. Eur J Pharmacol 1996;306:33-39.
27. Ferraro L, Tanganelli S, O'Connor WT, Antonelli T, Rambert F, Fuxe E. The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus. Neuroreport 1997;8:2883-2887.
28. Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert FA, Fuxe K. The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: Evidence for a preferential inhibition of striato-pallidal GABA transmission. Neurosci Lett 1998;253:135-138.
29. Fontan B, Fondaraï J, Micas M, Albarède J-L. Intérêt de la psychométrie informatisée dans l'appréciation de l'activité d'Olmifon® (Adrafinil) sur la vigilance et les performances cognitives des patients âgés en maison de retraite. Psychol Med 1990;22:253-267.
30. Fuxe K, Janson AM, Rosen L, et al. Evidence for a protective action of the vigilance promoting drug adrafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: An immunocytochemical and biochemical analysis. Exp Brain Res 1992;88:117-130.
31. Gold LH, Balster RL. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology (Berl) 1996;126:286-292;
32. Guyotat J. Intérèt de l'adrafiil dans le traitement des manifestations dépressives des malades âgés. Psychol Med 1987;1901-1910.
33. Hascoët M, Bourin M. A new approach to the light/dark test procedure in mice. Pharmacol Biochem Behav 1998;60:645-653.
34. Hascoët M, Bourin M, Payeur R, Lombet A, Peglion JL. Sigma ligand S14905 and locomotor activity in mice. Eur Neuropsychopharmacol 1995;4:481-9.
35. Israel L, Fondarai J, Lubin S, Salin B, Hugono R. L'adrafinil (Olmifon) et patients âgés ambulatoires. Efficacité, versus placebo, de l'Adrafinil sur l'éveil dans les activités de la vie quotidienne. Psychol Med 1989;21:1235-1255.
36. Jouvet M. Une nouvelle famille de médicaments pour améliorer l'éveil: les eugrégoriques. Journées d'étude sur le vieillissement, organisées par l'ORPHEM, Marseilles, France; March 25-26, 1987.
37. Kohler F, Lubin, S. Étude en médecine générale de l'intérêt thérapeutique d'Olmifon chez des malades présentant des symptomes précoces de vieillissement cérébral handicapant leur activité quotidienne. Étude ouverte pragmatique chez 304 patients. La Vie Médicale 1990;2:335-344.
38. Lagarde D, Batejat D, Van Beers P, Sarafian D, Pradella S. Interest of modafinil, a new psychostimulant, during a sixty-hour sleep deprivation experiment Fundam Clin Pharmacol 1995;9:271-279.
39. Lin J-S, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci USA 1993;93:14128-14133.
40. Mignot, E, Nishino S, Guilleminaut C, Dement WC. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994;17:435-437.
41. Milhaud CL, Klein M J. Effects de l'Adrafinil sur l'activité nocturne du macaque rhésus (Macaca mulatta). J Pharmacologie 1985;16:372-80.
42. Milgram NW, Siwak CT, Gruet P, Woehrle F, Callahan H. Oral administration of adrafinil improves discrimination learning in aged beagle dogs. Pharmacol Biochem Behav (In press).
43. Mitler MM, Walslebe J, Sangal RB, Hirshiowitz M. Sleep latency on the maintenance of wakefulness test (MWT) for 530 patients with narcolepsy while free of psychoactive drugs. Electroencephalogr Clin Neurophysiol 1998;107:33-38.
44. Moachon G, Clenet M, Lathuyere D, Rousselet, F. Pharmacokinetics of adrafinil (adra) and one of its metabolites after single oral dose. IUPHAR 9th International Congress of Pharmacology. London: MacMillan Press, 1984.
45. Nicolaidis S, De Saint Hillaire Z. Nonamphetamine awakening agent modafinil induces feeding changes in the rat. Brain Res Bull 1993;32:87-90.
46. Piérard C, Satabin P, Lagarde D, et al. Effects of a vigilance-enhancing drug, modafinil, on rat brain metabolism: A 2D COSY H-NMR study. Brain Res 1995;251:251-256.
47. Rambert, FA, Pessonnier J, de Sereville J-E, Pointeau, A-M., Duteil J. Profil psychopharmacologique originil de l'adrafinil chez la souris. J Pharmacologie 1986;17:37-52.
48. Rambert FA, Pessonnier J, Duteil J. Several aspects of adrafinil-induced activity in the mouse: Involvement of an alpha-adrenergic link. Proceedings of the 14th CINP Congress; Florence, Italy; June 19-24, 1984; Abstract P. 177.
49. Salteu B, Grunberger J, Linzmayer L, Stohr H. Pharmaco-EEG, psychometric and plasma level studies with two novel alpha-adrenergic stimulants CRL 40476 and 40028 (Adrafinil) in elderly. New Trends Exp Clin Psychiatry 1986;11:5-31.
50. Shelton J, Nishino S, Vaught J, Dement WC, Mignot E. Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep 1995;18:817-826.
51. Simon P. The quaking mice: A model for the study of drugs modifying central noradrenergic activity. Proceedings of the 30th CINP Congress; Jerusalem, Israel; June 1982.
52. Simon P, Chermat R, Puech AJ. Pharmacological evidence of the stimulation of central alpha adrenergic receptors. Prog Neuropsychopharmacol Biol Psychiatry 1983;7:183-186.
53. Siwak CT, Gruet P, Woehrle F, Muggenburg B, Murphey HL, Milgram NW. Comparison of the effects of adrafinil, propentofylline and nicergoline on spontaneous behavior of aged dogs. Submitted.
54. Siwak CT, Gruet P, Woehrle F, et al. Behavioral activating effects of adrafinil in aged canines. Submitted.
55. Strupp BJ, Bunsey M, Levitsky D, Kesler M. Time-dependent effects of post-trial amphetamine treatment in rats: Evidence for enhanced storage of representational memory. Behav Neural Biol 1991;56:62-76.
56. Tanganelli S, Fuxe K, Ferraro L, Janson AM, Bianchi C. Inhibitory effects of the psychoactive drug modafinil on γ-aminobutyric acid outflow from the cerebral cortex of the awake freely moving guinea-pig. Naunyn Schmiedeberg's Arch Pharmacol 1992;345:461-465.
57. Tanganelli S, Perez de la Mora M, Ferraro L, et al. Modafinil and cortical γ-aminobutryic acid outflow. Modulation by 5-hydroxytryptamine neurotoxins. Eur J Pharmacol 1995;273:63-71.
58. Touret M, Sallanon-Moulin M, Fages C, et al. Effect of modafinil-induced wakefulness on glutamine synthetase regulation in the rat brain. Mol Brain Res 1994;26:123-128.
59. Ueki A, Rosén L, Andbjer B, et al. Evidence for a preventive action of the vigilance-promoting drug modafinil against striatal ischemic injury induced by endothelin-1 in the rat. Exp Brain Res 1993;96:89-99.
60. Ueki A, Rosén L, Andbjer B, et al. The vigilance-promoting drug modafinil counteracts the reduction of tyrosine hydroxylase immunoreactivity and of dopamine stores in the male rat after a partial transection of the dopamine pathway. Exp Brain Res 1993;93:259-270.
61. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998;43:88-97.